This brand name is authorized in Nigeria.
The drug CIPNOX contains one active pharmaceutical ingredient (API):
1
|
UNII
4BA73M5E37 - CIPROFLOXACIN HYDROCHLORIDE
|
|
Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-5048 | Tablet | Cipnox 500 Tablets TAB 500 mg | Film-coated tablet Each tablet contains: Ciprofloxacin Hydrochloride equiv. to Ciprofloxacin BP 500 mg | 28/09/2021 |
| C4-0446 | Intravenous infusion | CIPNOX INFUSION INJ_SOL 200 mg/100 mL 1 X 100ML | CIPNOX INFUSION CIPNOX CIPROFLOXACIN 200MG/100ML POM INFUSION 1 X 100ML ANTIBIOTIC SUITELIFE PHARMACEUTICALS LTD 4, AYO DAVIES CLOSE, OFF EKOLOLU STREET, SURULERE, LAGOS STATE ABARIS HEALTHCARE PVT LTD PLOT NO. 1407-11, VILLAGE RAJPUR, TAL. KADI, DIST. MEHSANA-382 740, GUJARAT, INDIA GMP- SATIS; LR- SATIS; FEES- PAID; NP:NA 27/07/2018 R R R C4-0446 | 30/01/2020 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-5048, C4-0446 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.